International Journal of Advances in Rheumatology

» Advanced search

Paper of the Month - May, 2010

• View Archive »

  • Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials - March, 2012
    Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a Phase II, randomized, placebo-controlled, dose-finding trial - February, 2012
    Association between disease modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis - January, 2012
    Bone edema on magnetic resonance imaging is an independent predictor of rheumatoid arthritis development in patients with early undifferentiated arthritis - December, 2011
    Acquisition of the rheumatoid arthritis HLA shared epitope through microchimerism - November, 2011
    The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases - October, 2011
    MRI in early rheumatoid arthritis: synovitis and bone marrow oedema are independent predictors of subsequent radiographic progression - September, 2011
    Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle–Wells syndrome - August, 2011
    The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study - July, 2011
    Rheumatoid arthritis-interstitial lung disease-associated mortality - June, 2011
    Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans - May, 2011
    The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept - April, 2011
    Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study - March, 2011
    Musculoskeletal pain is associated with very low levels of vitamin D in men: results from the European Male Ageing Study - February, 2011
    Individual susceptibility to periprosthetic osteolysis is associated with altered patterns of innate immune gene expression in response to pro-inflammatory stimuli - January, 2011
    Rheumatologists’ awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy - December, 2010
    Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis - November, 2010
    Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease - October, 2010
    Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? - September, 2010
    Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register - August, 2010
    The role of dynamic contrastenhanced MRI in the differential diagnosis of psoriatic and rheumatoid arthritis - July, 2010
    Postpartum onset of rheumatoid arthritis and other chronic arthritides: results from a patient register linked to a medical birth registry - June, 2010
    Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study) - May, 2010
    Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial - April, 2010
    Involvement of MAPKs and NFkappaB in tumor necrosis factor alpha-induced vascular cell adhesion molecule 1 expression in human rheumatoid arthritis synovial fibroblasts - March, 2010
    DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis - February, 2010
    The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents - January, 2010
    The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial - 2009
    Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON ): a multicentre, double-blind, double-dummy, randomised controlled trial - 2009
    Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis - 2009